Thomas A. Vecchiolla - 21 Dec 2023 Form 4 Insider Report for Calidi Biotherapeutics, Inc. (CLDI)

Role: Director
Signature: /s/ Thomas Vecchiolla
Issuer symbol: CLDI
Transactions as of: 21 Dec 2023
Net transactions value: +$13,876
Form type: 4
Filing time: 26 Dec 2023, 19:52:21 UTC
Previous filing: 14 Sep 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CLDI	Common Stock	Award	$13,876	+7,709	+2.2%	$1.80	365,105	21 Dec 2023	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a grant of restricted stock units ("RSUs") subject to the conditions of the Restricted Stock Unit Award Agreement pursuant to the Issuer's 2023 Plan. Each RSU represents a right to receive one share of the Company's common stock upon vesting. The number of RSUs to be issued will equal to the amount due to the director for Board fees divided by the closing price for a share of the Issuer's common stock on December 21, 2023, of $1.80. The RSUs were granted in a transaction exempt under Rule 16b-3 to the Reporting Person. The shares of common stock underlying the RSUs immediately vested on the grant date.

Content

Represents a grant of restricted stock units ("RSUs") subject to the conditions of the Restricted Stock Unit Award Agreement pursuant to the Issuer's 2023 Plan. Each RSU represents a right to receive one share of the Company's common stock upon vesting. The number of RSUs to be issued will equal to the amount due to the director for Board fees divided by the closing price for a share of the Issuer's common stock on December 21, 2023, of $1.80. The RSUs were granted in a transaction exempt under Rule 16b-3 to the Reporting Person. The shares of common stock underlying the RSUs immediately vested on the grant date.